Research Spotlight

Fishing for enzymes deep in the ocean

Laurel Oldach
April 29, 2022

When a research team pulls up a trawling net from the ocean floor, researchers often scramble to douse the specimens in ethanol or formaldehyde. It’s important to prevent decay of organisms that usually die before they even reach the surface. But Anderson Garbuglio de Oliveira, a chemist studying marine bioluminescence, would rather they were frozen.

Gabriela Galeazzo
A bioluminescent coral

“If you throw a net in the ocean, you will probably find a lot of bioluminescent organisms,” he said. About 90% of deep sea species produce light; but that glow is almost invisible in bright daylight, and his shipboard colleagues are usually interested in other topics. To retrieve and freeze bioluminescent tissue samples before they are pickled in formaldehyde, he said, “I must be very quick.”

Back in the lab at the University of Sao Paulo, Oliveira’s research team investigates the activity of luciferase enzymes, which produce light through a reaction between oxygen and a family of substrate molecules. While some luminescence systems, such as those from comb jellies, are well understood, working with other organisms, such as segmented worms, is “very, very difficult,” Oliveira said, “because their systems are completely new. … Most of the time you have no idea what you’re dealing with.”

Biotechnologists have found numerous laboratory uses for the best-known luciferases, which come from jellies and fireflies. Still, surprisingly little is known about the other biochemical systems that produce light, a phenomenon that evolved on at least 94 independent occasions.

Oliveira is looking for enzymes with properties that could be biochemically interesting and lead to novel uses, such as detecting magnesium or calcium without needing to use fluorescence microscopy. He said, “You can find a lot of interesting things in these weird animals.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Laurel Oldach

Laurel Oldach is a former science writer for the ASBMB.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

When oncogenes collide in brain development
Journal News

When oncogenes collide in brain development

March 10, 2026

Researchers at University Medical Center Hamburg, found that elevated oncoprotein levels within the Wnt pathway can disrupt the brain cell extracellular matrix, suggesting a new role for LIN28A in brain development.

The data that did not fit
Research Spotlight

The data that did not fit

March 5, 2026

Brent Stockwell’s perseverance and work on the small molecule erastin led to the identification of ferroptosis, a regulated form of cell death with implications for cancer, neurodegeneration and infection.

Building a career in nutrition across continents
Profile

Building a career in nutrition across continents

March 3, 2026

Driven by past women in science, Kazi Sarjana Safain left Bangladesh and pursued a scientific career in the U.S.

Avoiding common figure errors in manuscript submissions
How-to

Avoiding common figure errors in manuscript submissions

Feb. 27, 2026

The three figure issues most often flagged during JBC’s data integrity review are background signal errors, image reuse and undeclared splicing errors. Learn how to avoid these and prevent mistakes that could impede publication.

Ragweed compound thwarts aggressive bladder and breast cancers
Journal News

Ragweed compound thwarts aggressive bladder and breast cancers

Feb. 26, 2026

Scientists from the University of Michigan reveal the mechanism of action of ambrosin, a compound from ragweed, selectively attacks advanced bladder and breast cancer cells in cell-based models, highlighting its potential to treat advanced tumors.

Lipid-lowering therapies could help treat IBD
Journal News

Lipid-lowering therapies could help treat IBD

Feb. 25, 2026

Genetic evidence shows that drugs that reduce cholesterol or triglyceride levels can either raise or lower inflammatory bowel disease risk by altering gut microbes and immune signaling.